Ellington Management Group LLC bought a new position in shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 26,400 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. grew its stake in Bellicum Pharmaceuticals by 47.1% during the third quarter. Schwab Charles Investment Management Inc. now owns 131,217 shares of the biopharmaceutical company’s stock worth $1,516,000 after purchasing an additional 41,995 shares during the period. Vanguard Group Inc. grew its stake in Bellicum Pharmaceuticals by 13.6% during the second quarter. Vanguard Group Inc. now owns 1,206,436 shares of the biopharmaceutical company’s stock worth $14,092,000 after purchasing an additional 144,854 shares during the period. Virtus Fund Advisers LLC acquired a new stake in Bellicum Pharmaceuticals during the fourth quarter worth approximately $343,000. Northern Trust Corp grew its stake in Bellicum Pharmaceuticals by 29.5% during the second quarter. Northern Trust Corp now owns 341,555 shares of the biopharmaceutical company’s stock worth $3,989,000 after purchasing an additional 77,760 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new stake in Bellicum Pharmaceuticals during the second quarter worth approximately $474,000. 54.57% of the stock is owned by institutional investors and hedge funds.
In other Bellicum Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker sold 260,600 shares of the firm’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $8.63, for a total value of $2,248,978.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 1,141,822 shares of company stock valued at $9,475,583 in the last three months. Insiders own 18.77% of the company’s stock.
Shares of Bellicum Pharmaceuticals Inc (BLCM) opened at $8.01 on Tuesday. The company has a quick ratio of 8.37, a current ratio of 8.37 and a debt-to-equity ratio of 0.41. Bellicum Pharmaceuticals Inc has a one year low of $5.02 and a one year high of $15.55. The company has a market capitalization of $267.23, a P/E ratio of -2.75 and a beta of 0.44.
Several research firms recently commented on BLCM. Cantor Fitzgerald set a $10.00 target price on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, March 13th. Zacks Investment Research cut Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 12th. ValuEngine cut Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. BidaskClub raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 4th. Finally, Wells Fargo cut Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 price objective for the company. in a research note on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $16.88.
ILLEGAL ACTIVITY NOTICE: “26,400 Shares in Bellicum Pharmaceuticals Inc (BLCM) Acquired by Ellington Management Group LLC” was originally published by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.thestockobserver.com/2018/03/20/26400-shares-in-bellicum-pharmaceuticals-inc-blcm-acquired-by-ellington-management-group-llc.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Want to see what other hedge funds are holding BLCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bellicum Pharmaceuticals Inc (NASDAQ:BLCM).
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.